CHMP recommends EU approval of seven medic...The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval at its December 2017 meeting, including two orphan medicines, and one … more ➔
reMYND in €350m diabetes deal with Novo Belgian reMYND N.V. has out licenced worldwide commercialisation rights for its small molecule programme ReS39 in diabetes to Novo Nordisk A/S. The drug impedes death of insulin-producing beta cells … more ➔
TB urine test outperforms standard of careA new, non-invasive tuberculosis urine test prevents common disadvantages of the standard tuberculin skin test: Measuring lipoarabinomannan glycan from M. tuberculosis, it detects the active disease … more ➔
LSP raises €280m for late-stage med-tech...Life sciences investment group LSP has launched the largest fund in Europe dedicated to late-stage medical technology assets, including diagnostics and digital health. more ➔
Aelin Therapeutics NV bags €27m in Serie...Belgian start-up company Aelin Therapeutics NV secured the funds to push development of candidate drugs arising from its Pept-in protein knockdown platform, which harnesses protein aggregation to induce … more ➔
ArgenX reports hints to efficacy of ARGX-1...Dutch llama antibody specialist ArgenX met the safety endpoint in a Phase II trial with ARGX 113 (efgartigimod), a first-in-class antibody that lowers pathogenic levels of IgG, in patients with the autoimmune … more ➔
Ortho markets predictive heart failure re-...In vitro diagnostics leader Ortho Clinical Diagnostics (Raritan, US) expands his assay portfolio with Sphingotecs first-in-class biomarker test that predicts residual edema and re-hospitalization in … more ➔
Advicenne raised a €27m IPO on Euronext...French based Advicenne has raised a €27m IPO on Euronext Paris, to develop paediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. more ➔
Researchers create druggable “love h...A European-Australian team of researchers has created a synthetic version of oxytocin that does not show the off-target effects mediated by its chemical analogon vasopressin. more ➔
FDA approves pan-tumour genomic profiling... Roche company Foundation Medicine Inc. (FMI) has been granted FDA approval for a diagnostic multiplex tumour profiling assay, which identifies a broad range of tumour markers in one single measurement. more ➔
